In this issue:
Atazanavir: no increased MI or CVA risk
HIV treatment: good hepatic safety
UGT1A1 gene variant linked to ATZ discontinuation
Boceprevir interactions with HIV PIs
EFV preferred over NVP in first-line HIV therapy?
Strategies for minimising NVP hepatoxicity
RAL/ABC/3TC: reassuring SPIRAL study data
Using the QRS-T angle to assess CV risk
Higher CD4 counts reduce risk of MetS
Laboratory monitoring on cART in the US
Please login below to download this issue (PDF)